Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies.

ABSTRACT: Accumulating evidence confirmed that many dysregulated signaling pathways and aberrant genetic alterations contribute to the oncogenesis and heterogeneity of lymphoid malignancies. Therapeutically targeting dysregulating signaling pathways and their hidden oncogenic biomarkers are becoming available, but did not show desired therapeutic effect in current clinical practice. It is meaningful to further understand the underlying mechanisms of the dysregulated signaling pathways and to address the potential utility of pathway-related biomarkers. To precisely identify the dysregulation of signaling pathways and the "driver" oncogenic biomarkers, as well as to develop reliable and reproducible risk-stratification based on biomarkers will be challenging. Nevertheless, pathway-based targeted thera

SUBMITTER: Sun RF 

PROVIDER: S-EPMC5938286 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature